The U.S. Supreme Court recently held in Association for Molecular Pathology v. Myriad Genetics that isolated gene sequences are not patent eligible because they are naturally occurring nucleic acids.  This ruling brings new opportunities as well as new challenges to the biotech industry of which investors, inventors, and researchers need to be aware.Continue reading→